41st Annual Miami Breast Cancer Conference® - Abstracts

home / journals / mbcc-suppl / 41st-annual-miami-breast-cancer-conference---abstracts
31 Adjuvant Abemaciclib Plus Endocrine Therapy for HR+, HER2–, High-Risk Early Breast Cancer: Results From a Preplanned MonarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes

31 Adjuvant Abemaciclib Plus Endocrine Therapy for HR+, HER2–, High-Risk Early Breast Cancer: Results From a Preplanned MonarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes

Hope S. Rugo, MD;Nadia Harbeck, MD, PhD;Priya Rastogi, MD;Joyce O’Shaughnessy, MD;Frances Boyle;Javier Cortés, MD;Matthew P. Goetz, MD;Erika P. Hamilton, MD;Chiun-Sheng Huang;Elżbieta Senkus;Alexey Tryakin;Patrick Neven, MD, PhD;Jens Huober, MD;Ran Wei;Valérie André;Maria Munoz;Belen San Antonio;Ashwin Shahir;Miguel Martin, MD, PhD;Stephen Johnston
July 9th 2024
ArticleMedical Oncology
32 Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo for Early-Stage Triple- Negative Breast Cancer: Updated Event-Free Survival Results From the Phase 3 KEYNOTE-522 Study

32 Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo for Early-Stage Triple- Negative Breast Cancer: Updated Event-Free Survival Results From the Phase 3 KEYNOTE-522 Study

Peter Schmid, MD;Javier Cortes;Rebecca Dent, MD;Lajos Pusztai, MD, DPhil;Heather McArthur, MD, MPH;Sherko Kümmel;Carsten Denkert;Yeon Hee Park;Rina Hui;Nadia Harbeck, MD, PhD;Masato Takahashi;Theodoros Foukakis;Marie-Ange Mouret-Reynier;Marta Ferreira;Seock-Ah Im;Fatima Cardoso;Yu Ding;Wilbur Pan;Konstantinos Tryfonidis;Joyce O’Shaughnessy, MD
July 7th 2024
ArticleMedical Oncology
33 MammaPrint® and BluePrint® Predict Anthracycline Chemosensitivity in Patients With HR+HER2– Early-Stage Breast Cancer Enrolled in FLEX

33 MammaPrint® and BluePrint® Predict Anthracycline Chemosensitivity in Patients With HR+HER2– Early-Stage Breast Cancer Enrolled in FLEX

William Audeh, MD;Nicole Chmielewski-Stivers;Harshini Ramaswamy;Andrea Menicucci
June 30th 2024
ArticleMedical Oncology
34 How Mobile Computing Devices Offer Support for Classic and Molecular Multidisciplinary and Tumor Boards

34 How Mobile Computing Devices Offer Support for Classic and Molecular Multidisciplinary and Tumor Boards

Glenn Tisman
June 29th 2024
ArticleMedical Oncology
35 Impact of Comorbidities on Real-World (rw) Clinical Outcomes of Patients (pts) With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2–Negative (HR+/HER2–) Advanced Breast Cancer (ABC) Treated With Palbociclib (PAL) and Enrolled in POLARIS

35 Impact of Comorbidities on Real-World (rw) Clinical Outcomes of Patients (pts) With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2–Negative (HR+/HER2–) Advanced Breast Cancer (ABC) Treated With Palbociclib (PAL) and Enrolled in POLARIS

Debu Tripathy, MD;Joanne L. Blum, MD, PhD;Meghan S. Karuturi;Monica Z. Montelongo;Zhe Zhang;Eric Gauthier;Gabrielle Rocque
June 25th 2024
ArticleMedical Oncology
36 MONARCH 3: Final Overall Survival Results of Abemaciclib Plus a Nonsteroidal Aromatase Inhibitor as First-Line Therapy for HR+/HER2– Advanced Breast Cancer

36 MONARCH 3: Final Overall Survival Results of Abemaciclib Plus a Nonsteroidal Aromatase Inhibitor as First-Line Therapy for HR+/HER2– Advanced Breast Cancer

Matthew P. Goetz, MD;Masakazu Toi;Jens Huober, MD;Joohyuk Sohn;Oliver Trédan;In Hae Park;Mario Campone;Shin-Cheh Chen;Luis Manuel Manso;Shani Paluch-Shimon;Orit C. Freedman;Joyce A. O’Shaughnessy;Xavier Pivot;Sara M. Tolaney, MD, MPH;Sara A. Hurvitz, MD;Antonio Llombart;Valérie André;Abhijoy Saha;Gertjan van Hal;Ashwin Shahir;Hiroji Iwata;Stephen R.D. Johnston
June 23rd 2024
ArticleMedical Oncology
37 Estimating the Direct and Indirect Resource Burden of Treatment Management With Current Standard of Care or Elacestrant for ER+, HER2–, ESR1-Mutated Advanced or Metastatic Breast Cancer Patients: A Population- Level Provider Model

37 Estimating the Direct and Indirect Resource Burden of Treatment Management With Current Standard of Care or Elacestrant for ER+, HER2–, ESR1-Mutated Advanced or Metastatic Breast Cancer Patients: A Population- Level Provider Model

Gregory Vidal, MD, PhD;Frank Cinfio;Jack Badaracco;Corey Pelletier;Matthew Gitlin
June 22nd 2024
ArticleMedical Oncology
38 Influence of Race on Attainment of Textbook Oncologic Outcome Following Modified Radical Mastectomy for Breast Cancer

38 Influence of Race on Attainment of Textbook Oncologic Outcome Following Modified Radical Mastectomy for Breast Cancer

Lucia Castro Hernandez;Natalie Ceballos;Alejandra Ergle;Shenea Samuels;Zanieb Shatawi;Omar H. Llaguna
June 12th 2024
ArticleSurgical Oncology
39 The Influence of Reconstruction Type on Outcomes in Women Undergoing Mastectomy With Immediate Reconstruction: A Nationwide Study

39 The Influence of Reconstruction Type on Outcomes in Women Undergoing Mastectomy With Immediate Reconstruction: A Nationwide Study

Lucia Castro Hernandez;Zaineb Shatawi;Joshua P. Parreco;Lucy M. De La Cruz
June 9th 2024
ArticleSurgical Oncology
40 Ethnic Disparities in Complication Rates and Outcomes of Nipple-Sparing Mastectomy: A Comprehensive Analysis

40 Ethnic Disparities in Complication Rates and Outcomes of Nipple-Sparing Mastectomy: A Comprehensive Analysis

Arianna Cavalli;Fardeen Bhimani;Lesley G. Coe;Liane N. Obaid;Anjuli Gupta;Jessica Pastoriza;Sheldon Feldman;Maureen McEvoy
June 8th 2024
ArticleSurgical Oncology
41 A Case Series of Sarcomas

41 A Case Series of Sarcomas

Chu-Yu Cheng;Chris Alving-Trinh;Ibironke Adelaja;Deborah Gumina
May 31st 2024
ArticleSurgical Oncology
42 Transitional Lymphedema: Understanding the Temporal Dynamics Post-Axillary Surgery

42 Transitional Lymphedema: Understanding the Temporal Dynamics Post-Axillary Surgery

Anshumi Desai;Victoria Dahl;Carolina Padilla;Seraphina Choi;Eli Avisar
May 29th 2024
ArticleSurgical Oncology
43 Impact of Lymphatic Microsurgical Preventing Healing Approach (LYMPHA) on Postoperative Complication Rates in Mastectomy With Immediate Prosthetic-Based Breast Reconstruction

43 Impact of Lymphatic Microsurgical Preventing Healing Approach (LYMPHA) on Postoperative Complication Rates in Mastectomy With Immediate Prosthetic-Based Breast Reconstruction

Anshumi Desai;Emily Finklestein;Meaghan Clark;Rohan Mangal;Iago De Castro Silva;Susan B. Kesmodel;Kristin E. Rojas;Devinder Singh;Kyle Xu;Juan Catinchi-Mella
May 29th 2024
ArticleSurgical Oncology
44 Variant of Uncertain Significance (VUS) Genetic Testing Results and Mastectomy Choice in Lumpectomy-Eligible Patients

44 Variant of Uncertain Significance (VUS) Genetic Testing Results and Mastectomy Choice in Lumpectomy-Eligible Patients

Osvaldo Nunez;Vasanth Govind;Tizita Wolde;Rainya Heath;Talia R. Donenberg;Rachel Silva-Smith;Marie B. Jeanjean;Jessica Moore;Jessica Crystal;Susan B. Kesmodel;Kristin E. Rojas
May 28th 2024
ArticleSurgical Oncology
45 Application of the 7-Gene Biosignature in Palpable Versus Nonpalpable Ductal Carcinoma In Situ in a Black Patient Population: Does Palpability Suggest a More Aggressive Genomic Risk?

45 Application of the 7-Gene Biosignature in Palpable Versus Nonpalpable Ductal Carcinoma In Situ in a Black Patient Population: Does Palpability Suggest a More Aggressive Genomic Risk?

Amy Jeng;Cristina Solis-Pomales;Kseniya Roudakova;J. Jamie Alberty-Oller
May 26th 2024
ArticleSurgical Oncology
46 Comparative Analysis of Breast Conserving Therapy vs Mastectomy in Multifocal and Multicentric Breast Cancer: A Review of the Literature

46 Comparative Analysis of Breast Conserving Therapy vs Mastectomy in Multifocal and Multicentric Breast Cancer: A Review of the Literature

Kelly Kapp;Lucy M. De La Cruz;Carmen de Carvajal;Nathan Wong;Ashwini Paranjpe
May 25th 2024
ArticleSurgical Oncology
47 Can We Identify Factors That Predict DCIS Upgrade to Invasive Cancer at Mastectomy?

47 Can We Identify Factors That Predict DCIS Upgrade to Invasive Cancer at Mastectomy?

Kelly Mackessy;Christopher Verdone;Karisa Beebe;Valerie L. Staradub, MD;Candice Ford;Kristen Skonieczny;Alexandra Haraczy;Alexandra Ford;Hyeon Jeong;Esha Parikh;Dawn Johnson Leonard
May 24th 2024
ArticleSurgical Oncology
48 The Era ‘or Error’ of Second Localization Procedures

48 The Era ‘or Error’ of Second Localization Procedures

Nicole Nelson;Jennifer Den;H. Colleen Silva;Biai Digbeu;Flavia Pselman;Angelica Robinson;V. Suzanne Klimberg, MD
May 23rd 2024
ArticleSurgical Oncology
49 The Influence of Race on Complications in Breast Conservation Surgery: A Single Institution Study

49 The Influence of Race on Complications in Breast Conservation Surgery: A Single Institution Study

Liane N. Obaid;Janice S. Zhang;Grace Y. Lee;Fardeen Bhimani;Lesley G. Coe;Arianna Cavalli;Anjuli Gupta;Jessica Pastoriza;Sheldon Feldman;Maureen McEvoy
May 22nd 2024
ArticleSurgical Oncology
51 Ductal Carcinoma In Situ With Microinvasion on Biopsy—What Are the Predictors of Upstaging?

51 Ductal Carcinoma In Situ With Microinvasion on Biopsy—What Are the Predictors of Upstaging?

Priyanka Parmar;Jessica Pastorzia;Cien Huang
May 18th 2024
ArticleSurgical Oncology
52 UK Experience of Non-Radioisotope, Non-Magnetic Guided Breast Wide Local Excision and Sentinel Node Biopsy

52 UK Experience of Non-Radioisotope, Non-Magnetic Guided Breast Wide Local Excision and Sentinel Node Biopsy

Alessio Vinci;Vassilis Pitsinis;Bushra Riaz;Connie Baume-Kennedy
May 17th 2024
ArticleImaging and Radiology
53 The Utility of Sentinel Lymph Node Biopsy in High-Grade Ductal Carcinoma In Situ

53 The Utility of Sentinel Lymph Node Biopsy in High-Grade Ductal Carcinoma In Situ

Lauren Westcott;Caroline Breit;Ellen Wilson;Darby Dwyer;Holly Hodge;Lucy Wallace;Michael Grant
May 16th 2024
ArticleSurgical Oncology
54 The Evaluation of Expression Levels of CXCR4, CXCL12, and LASP1 Genes in Peripheral Blood Samples of Breast Cancer Patients

54 The Evaluation of Expression Levels of CXCR4, CXCL12, and LASP1 Genes in Peripheral Blood Samples of Breast Cancer Patients

Arash Adamnejad Ghafour;Seref Bugra Tuncer
May 16th 2024
ArticleMultidisciplinary Specialties
55 Language as a Barrier to Deep Inspiration Breath Hold (DIBH) Radiation Therapy for Left Breast Cancer

55 Language as a Barrier to Deep Inspiration Breath Hold (DIBH) Radiation Therapy for Left Breast Cancer

Justin Choi;Fleure Gallant;Bernadine R. Donahue, MD;Jonathan Klein
May 14th 2024
Article
56 Predictive Factors Correlating With Pathologic Complete Response Rates in Racially Diverse, Minority Populations Receiving Neoadjuvant Therapy for HR+/HER2– Breast Cancer

56 Predictive Factors Correlating With Pathologic Complete Response Rates in Racially Diverse, Minority Populations Receiving Neoadjuvant Therapy for HR+/HER2– Breast Cancer

Lesley G. Coe;Fardeen Bhimani;Liane N. Obaid;Arianna Cavalli;Anjuli Gupta;Jessica Pastoriza;Sheldon Feldman;Maureen McEvoy
May 14th 2024
ArticleMultidisciplinary Specialties
57 Addressing Barriers to Identifying Patients With HER2-Low Metastatic Breast Cancer in a Large Community Oncology Practice

57 Addressing Barriers to Identifying Patients With HER2-Low Metastatic Breast Cancer in a Large Community Oncology Practice

Lauren Carpenter;Kelli Corona;Bob Phelan;Shenitha Edwards
May 13th 2024
ArticleMultidisciplinary Specialties
58 Prospective Longitudinal Assessment of Financial Toxicity Among Breast Cancer Patients

58 Prospective Longitudinal Assessment of Financial Toxicity Among Breast Cancer Patients

Jonathan Klein;Joshua Feinberg;Mukuhi Ng’ang’a;Ashley Anderson;Vijaya Natarajan;Pasang Sherpa;Fleure Gallant;David Berlach;Ezekiel Sanchez;Charusheela Andaz
May 12th 2024
ArticleMultidisciplinary Specialties
59 Acceptability of Microbiome Sampling-Based Surgical Oncology Research in Minority Breast Cancer Patients

59 Acceptability of Microbiome Sampling-Based Surgical Oncology Research in Minority Breast Cancer Patients

Daniel A. Gomez;Tizita Wolde;Tulay Koru-Sengul;Kristin E. Rojas
May 11th 2024
ArticleSurgical Oncology
60 Racial Disparities in Hospitalization Outcomes Among Women With Metastatic Breast Cancer in the United States by Palliative Care Utilization

60 Racial Disparities in Hospitalization Outcomes Among Women With Metastatic Breast Cancer in the United States by Palliative Care Utilization

Inimfon Jackson;Debu Tripathy, MD
May 10th 2024
ArticleMultidisciplinary Specialties
61 High-Risk Screening Compliance in Women Diagnosed With Breast Cancer and a History of Thoracic Radiation Prior to Age 30

61 High-Risk Screening Compliance in Women Diagnosed With Breast Cancer and a History of Thoracic Radiation Prior to Age 30

Daniella Nevid;Elisa Port;Tara Balija
May 10th 2024
ArticleImaging and Radiology
<123>